External Evaluations

Sustainability Evaluations

Won Special Encouragement Award at the "Ikumen Enterprise Award 2018, in the Work-Life Balance Support Category"

As part of the Ministry of Health, Labour and Welfare's Ikumen Project that supports men's active participation in child-rearing and promotes their taking of childcare leave, the award commends companies and individuals who serve as models that promote a working environment conducive to giving birth and raising children with peace of mind while continuing to work. The Company won the Special Encouragement Award in the Work-Life Balance Support Category.

Acquired accreditation mark based on the Act on Advancement of Measures to Support Raising Next-Generation Children

The Act on Advancement of Measures to Support Raising Next-Generation Children came into effect in 2005. In accordance with this law, companies that formulate action plans to support child-rearing by employees, achieve planned targets, and meet certain standards are eligible for certification by the Minister of Health, Labour and Welfare. The Company has been certified for six consecutive years since 2007. Among companies that had already been "Kurumin" certified, Mitsubishi Tanabe Pharma was "Platinum Kurumin" certified in July 2019.

Acquired "Eruboshi" certification mark

In accordance with the Act on Promotion of Women's Participation and Advancement in the Workplace, which came into effect in 2016, companies that formulate action plans to promote active careers for female employees and achieve excellent results with related initiatives are eligible for certification by the Minister of Health, Labour and Welfare. The Eruboshi mark demonstrates that a company has received this certification. In 2016, we received "Eruboshi," the highest level of certification, which is based on the Act on Promotion of Women's Participation and Advancement in the Workplace.

Selected as "Outstanding Enterprise in Health and Productivity Management ‐ White 500"

The "Outstanding Enterprise in Health and Productivity Management Certification System," which was established by the Ministry of Economy, Trade and Industry (METI) in 2016, is a system for recognizing companies and groups that are implementing especially strong health and productivity management. Of these companies, the White 500 program certifies large corporations that implement excellent health and productivity management in cooperation with their health insurance providers. This program, which is offered jointly by METI and Nippon Kenko Kaigi, is intended to expand the number of companies that are implementing health and productivity management. The program will certify 500 companies by 2020. Mitsubishi Tanabe Pharma has been selected for four consecutive years since 2017.

Acquired Certification as a Leading Company in the Support of Active Careers for Women

Each year, in accordance with established standards, Osaka City certifies companies and groups that are actively striving to establish environments that support active careers for women. Mitsubishi Tanabe Pharma received this certification in 2016.

Received Award of Excellence at the 3rd Working Women Empowerment Awards

The Japan Productivity Center implements this wide-ranging award program for organizations that are conducting original, innovative initiatives with the aim of empowering women and increasing productivity. In June 2018, we received an award of excellence.

Awarded the Gold Prize in the PRIDE INDEX for LGBT Issues

The PRIDE INDEX, established by "work with Pride," a private organization, is Japan's first index that evaluates the initiatives of companies and organizations related to sexual minorities such as LGBTs. MTPC was awarded the GOLD Prize in the PRIDE INDEX 2019.

Received the “Cancer Control Promotion Partner Award” (in the Treatment and Work Balance Category)

In March 2020, our company's system of supporting a balance between medical treatment and one's work was highly acclaimed for its ability to flexibly respond to individual cases, and we received the Award for Companies Promoting Cancer Control (in the Treatment and Work Balance category)” in the Action Plan for Promotion of Cancer Control, a project commissioned by the Ministry of Health, Labour and Welfare.

Product and Technology Evaluations

Received the 3rd Japan Medical Research and Development Awards' Prime Minister Prize

In January 2020, Mitsubishi Tanabe Pharma Corporation received the Japan Medical Research and Development Awards' Prime Minister Prize together with Professor Yoshikatsu Kanai of Osaka University for “Molecular Identification of SGLT2 and Development of its Inhibitor.” The Japan Medical Research and Development Awards, sponsored by the Japanese government, are intended to deepen the interest and understanding of the public in recognition of achievement, and increase incentives for researchers for cases that have greatly contributed to the promotion of research and development in the medical field. The Prime Minister Prize is awarded to individuals in recognition of outstanding achievement.

Received the 48th Japan Industrial Technology Awards' Prime Minister Prize

In April 2019, at the 48th Japan Industrial Technology Awards sponsored by Nikkan Kogyo Shimbun, we were presented the highest award, the Prime Minister's Prize for “Fingolimod hydrochloride for the treatment of multiple sclerosis,” which was discovered through collaborative research with Mitsui Sugar Co., Ltd., and Professor Emeritus Tetsuro Fujita of Kyoto University.

The Japan Industrial Technology Awards recognize R&D and practical technologies that have produced remarkable achievements in industrial and societal development.

Winner of the 51st Ichimura Prize in Industry for Outstanding Achievement

In April 2019, Canagliflozin, which we discovered, won “The Ichimura Prize in Industry for Outstanding Achievement.” The Ichimura Prize in Industry (sponsored by the Ichimura Foundation for New Technology) is presented to technology developers or groups who have contributed to developments and achievements in the industrial field based on their creation of outstanding made-in-Japan technology, and Outstanding Achievement is the highest ranking award.

Received The 2019 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology, Awards for Science and Technology (Development Category)

In April 2019, the “Invention and development of a new entirely Japan-made DPP4 inhibitor” Teneligliptin by Mitsubishi Tanabe Pharma was acclaimed and received the Award for Science and Technology (Development Category) at the FY2019 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology.

The Commendation for Science and Technology (sponsored by the Ministry of Education, Culture, Sports, Science and Technology) is an award intended to increase the motivation of people engaged in science and technology and contribute to improving Japan's science and technology standards.

Received the Breakthrough Award of the Division of Medicinal Chemistry, Pharmaceutical Society of Japan (PSJ)

In November 2019, Evocalcet, a drug for the treatment of secondary hyperparathyroidism, discovered by the Company, received the PSJ's Breakthrough Award of the Division of Medicinal Chemistry. The award is sponsored by the PSJ and is presented to researchers who have achieved research progress including breakthroughs that contribute to drug discovery development. It is awarded for “innovative research on drugs or bioactive compounds with novel chemical structures” and “innovative research that contributes to drug discovery research through new technologies and methods.”

Received the Good Design Award 2019

In October 2019, the ethical drug Simponi® Subcutaneous Injection 50 mg Autoinjector received the Good Design Award 2019 (sponsored by Japan Institute of Design Promotion). The Good Design Award was established in 1957 and is Japan's only comprehensive design evaluation and recommendation structure. The global design award is held every year for the purpose of improving the quality of life and leveraging design to solve social issues. The award-winning “G Mark” symbol is widely recognized as a symbol of excellence in design.

Received the Award for Hangover Antidote at the 32nd “Hit Product Award/Topic Product Award (in the Pharmaceutical/Designated Quasi-drug Category)"

In June 2020, the over-the-counter drug “Urusoukon” received the Award for Hangover Antidote at the 32nd Hit Product Award/Topic Product Award in the Pharmaceuticals/Designated Quasi-drug Category (sponsored by Drugmagazine Co., Ltd. and Yachiyokai). Since the 29th Hit Product Award/Topic Product Award, this marks the fourth consecutive year that Tanabe Mitsubishi Pharma has won this award.